Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Novartis
 More »

  • GEN's List of Molecular Millionaires
    Ranking highest among big pharmas, at No. 14, was not a current pharma executive but a retired chairman. The CEOs of two other pharma giants-Joseph Jimenez of Novartis and Ian C. ...
    10-15-2013
  • Novartis Inks Agreement for ImmunoGen's "TAP" ADC Technology
    Novartis agreed to license ImmunoGen's Targeted Antibody Payload (TAP) antibody-drug ... Novartis has responsibility for developing, manufacturing, and marketing any products that ...
    10-11-2013
  • JobWatch: Novartis Trims California Workforce
    and redeploy resources to meet the needs of the business," Novartis told GEN in a statement earlier this week. "Novartis plans to strengthen the focus of the Emeryville site on its ...
    10-9-2013
  • A*STAR, Debiopharm Team Up to Develop Epigenetic Cancer Target
    The center is directed by Alex Matter, M.D., who was also the global head of oncology research for Novartis Pharmaceuticals. "This partnership strengthens our presence in Asia in a ...
    10-7-2013
  • Eppendorf Sponsoring Shared Lab Space at Cambridge, MA
    Gold sponsors include Novartis Institutes for Biomedical Research, Cushman & Wakefield, and Cooley. MIT Investment Management is LabCentral's real estate partner. LabCentral, which ...
    10-4-2013
  • Young Companies in the Money: 25 Firms to Watch
    ... A/S (co-lead), and existing investors Novartis Venture Funds, Kearny Venture Partners, ... BB Biotech Ventures (new investor) and Novartis Venture Fund (existing investor) ...
    10-2-2013
  • FDA Speeds Things Up
    Breakthrough Therapy Designation Is Changing How the Agency Operates The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012. FDASIA ...
    10-1-2013
  • Malvern Instruments Acquires NanoSight
    As of May, NanoSight had installed more than 600 systems worldwide for customers that include pharma giants such as GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Roche, as ...
    9-30-2013
  • Employing Open Access LC/MS In Support of Recombinant Protein...
    This webinar will discuss how Novartis has deployed an open access LC/MS platform for biochemists and biologists to analyze their own recombinant proteins What You Will Learn ...
    9-26-2013
  • Takeover Targets: Who Is First on the List?
    ... worldwide rights have been licensed to Novartis (Phase II); INCB24360 for metastatic ... a $25 million milestone payment from Novartis once it formally launched the Phase II ...
    9-24-2013
  • Sanofi Opens Cancer Research Hub in Cambridge, MA
    Sanofi is one of several biopharma giants that are expanding in Massachusetts: Novartis, Pfizer, and Vertex Pharmaceuticals are set to open new sites over the next year. The sites ...
    9-20-2013
  • Top 40 Molecular Millionaires
    ... The CEOs of two other pharma giants-Joseph Jimenez of Novartis, and Ian C. Read of ... The CEOs of two other pharma giants-Joseph Jimenez of Novartis, and Ian C. Read of ...
    9-19-2013
  • JobWatch: Praying for a Massachusetts Miracle
    Pier on the South Boston waterfront; and new Cambridge, MA, sites for Biogen Idec, Novartis, and Pfizer. "Some of the expansion we thought we'd see reflected in the 2012 numbers ...
    9-18-2013
  • Revived GenVec Withdraws Dissolution Plan; New CEO Named
    a hearing-loss collaboration with Novartis-and has led to changes at the top. ... potential milestone payments from Novartis, we have cash, cash equivalents, and ...
    9-4-2013
  • FDA Speeds Things Up
    What's happened so far with breakthrough therapy designation? The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012. FDASIA ...
    9-3-2013
  • More »

    Journal Articles

  • An Interview with Doriano Fabbro, Ph.D., Novartis Biomedical...
    Vicki Glaser
    ASSAY and Drug Development Technologies
    An Interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute ASSAY and Drug Development Technologies
  • An Interview with Jeremy S. Caldwell, Ph.D., Executive Director...

    ASSAY and Drug Development Technologies
    An Interview with Jeremy S. Caldwell, Ph.D., Executive Director, Molecular and Cellular Biology, Lead Discovery and Genomics, Genomics Institute of the Novartis Research Foundation ...
  • Effect of Different Dose Schedules of 0.15% Unoprostone Isopropyl...
    Kirk N. Gelatt, Edward O. Mackay, Thomas Dashiell, Alison Biken
    Journal of Ocular Pharmacology and Therapeutics
    The changes in intraocular pressure (IOP) and pupil size (PS) after instillations of 0.15% unoprostone isopropyl (Rescula, Novartis Ophthalmics, Duluth, GA) were investigated in ...
  • Formoterol by Pressurized Metered-Dose Aerosol or Dry Powder...
    Vito Brusasco, G. Walter Canonica, Roberto Dal Negro, Giorgio Scano, Pierluigi Paggiaro, Leonardo M. Fabbri, Giovanni Barisione, Gennaro D'Amato, Guido Varoli, Michele Baroffio, Manlio Milanese, Carlo Mereu, Emanuele Crimi
    Journal of Aerosol Medicine and Pulmonary Drug Delivery
    Italy), with formoterol by dry powder inhaler (DPI) (Foradil® Aerolizer®, Novartis Pharmaceuticals) and placebo, in reducing airflow obstruction and lung ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll